Geographic Atrophy
📧 Sign up to get email alerts when something new happens for Geographic Atrophy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) [Phase 2]
Phase 2 trial of Galegenimab (FHTR2163) in geographic atrophy due to age-related macular degeneration was terminated; results were posted.
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study [Phase 2]
A Phase 2 long-term follow-up study evaluating the safety of GT005 in participants with geographic atrophy secondary to age-related macular …
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration [Phase 2]
Phase 2 trial results update evaluating oral minocycline for geographic atrophy in age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2023-12-28Clinical Trial Update: A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) [Phase 3]
Phase 3 safety and efficacy study of intravitreal Zimura (avacincaptad pegol) for geographic atrophy and age-related macular degeneration ha…
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA [Phase 2]
Phase 2 trial results update for elamipretide in age-related macular degeneration with non-central geographic atrophy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-10-16Clinical Trial Update: A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration [Phase 2]
Phase 2 long-term safety and tolerability study of Galegenimab (FHTR2163) in geographic atrophy due to age-related macular degeneration has …
-
CLINICAL_TRIALS trial_result · 2023-09-15Clinical Trial Update: A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy [Phase 1]
Phase 1 study evaluating tolerability of different doses of BI 754132 in geographic atrophy due to age-related macular degeneration; trial t…
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration [Phase 3]
Phase 3 trial comparing intravitreal APL-2 therapy to sham injections in geographic atrophy due to age-related macular degeneration has comp…
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration [Phase 3]
Phase 3 trial comparing intravitreal APL-2 vs sham injections in geographic atrophy due to age-related macular degeneration has completed wi…
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD [Phase 2]
Phase 2 trial evaluating metformin to slow geographic atrophy progression in age-related macular degeneration has completed with posted resu…
-
CLINICAL_TRIALS trial_result · 2023-05-11Clinical Trial Update: Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Phase 2, Phase 3]
A Phase 2/Phase 3 trial update for Zimura in geographic atrophy due to dry age-related macular degeneration. The study is completed and resu…
-
FDA approval · 2023-02-17FDA Approved: SYFOVRE — Original Application (Apellis Pharmaceuticals, Inc.)
FDA approved SYFOVRE (pegcetacoplan) from Apellis Pharmaceuticals for geographic atrophy associated with age-related macular degeneration, m…
-
CLINICAL_TRIALS research · 2022-11-04Clinical Trial Update: Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) [Phase 2, Phase 3]
Clinical trial update for ORACEA in geographic atrophy (Phase 2/3) is completed.
-
CLINICAL_TRIALS trial_result · 2020-10-06Clinical Trial Update: Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy [Phase 2]
A Phase 2 study evaluating pegcetacoplan (APL-2) for geographic atrophy has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-06-23Clinical Trial Update: A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy [Phase 2]
Phase 2 trial update on subretinal administration of CNTO 2476 in geographic atrophy, reporting safety and clinical response outcomes with r…
-
CLINICAL_TRIALS trial_result · 2020-05-29Clinical Trial Update: Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD [Phase 1, Phase 2]
Clinical trial update for subretinal implantation of human embryonic stem cell-derived RPE cells in advanced dry AMD (Phase 1/Phase 2).
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD [NA]
Completed results for a trial of subthreshold laser treatment for reticular pseudodrusen and geographic atrophy due to age-related macular d…
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration [Phase 3]
Phase 3 trial of lampalizumab for geographic atrophy due to age-related macular degeneration was terminated with posted results in 2019.
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration [Phase 2]
Phase 2 safety and efficacy trial of brimonidine intravitreal implant for geographic atrophy due to age-related macular degeneration was ter…
-
CLINICAL_TRIALS trial_result · 2019-03-14Clinical Trial Update: A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration [Phase 3]
Phase 3 trial investigating lampalizumab for geographic atrophy due to age-related macular degeneration was terminated; results posted in 20…
-
CLINICAL_TRIALS trial_result · 2019-02-21Clinical Trial Update: An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy [Phase 2]
An extension study to evaluate long-term safety of lampalizumab in geographic atrophy participants; terminated with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-02-19Clinical Trial Update: A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy [Phase 2]
Phase 2 trial evaluating intravitreal lampalizumab every two or four weeks in geographic atrophy completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) [Phase 3]
Phase 3 trial update on long-term safety of lampalizumab intravitreal injections in geographic atrophy due to age-related macular degenerati…
-
CLINICAL_TRIALS trial_result · 2018-12-19Clinical Trial Update: CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA) [Phase 2]
Phase 2 clinical trial update for CLG561 as monotherapy and in combination with LFG316 in Geographic Atrophy; study completed with results p…
-
CLINICAL_TRIALS trial_result · 2018-07-27Clinical Trial Update: Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) [Phase 2]
Phase 2 trial of intravitreal LFG316 in geographic atrophy and age-related macular degeneration has completed; results posted in 2018.